AbbVie (AbbVie) Interest Expense

: $-2,224 Mil (TTM As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. AbbVie's interest expense for the three months ended in Dec. 2023 was $ -564 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-2,224 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. AbbVie's Operating Income for the three months ended in Dec. 2023 was $ 3,477 Mil. AbbVie's Interest Expense for the three months ended in Dec. 2023 was $ -564 Mil. AbbVie's Interest Coverage for the quarter that ended in Dec. 2023 was 6.16. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

AbbVie Interest Expense Historical Data

The historical data trend for AbbVie's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbbVie Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

-1,784.00

-2,454.00

-2,423.00

-2,230.00

-2,224.00

AbbVie Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense																-566.00	-553.00	-552.00	-555.00	-564.00

AbbVie Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2,224 Mil.

AbbVie (NYSE:ABBV) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

AbbVie's Interest Expense for the three months ended in Dec. 2023 was $-564 Mil. Its Operating Income for the three months ended in Dec. 2023 was $3,477 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $52,194 Mil.

AbbVie's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	3477	/	-564
	=	6.16

The higher the ratio, the stronger the company's financial strength is.

AbbVie (AbbVie) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (NYSE:ABBV) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

ABBV:Mexico 1ABBV:Italy 4ABd:UK 0QCV:UK 4AB0:Germany 4AB:Germany 4AB:Germany 4AB:Germany ABBV:Canada ABBV34:Brazil ABBV:Austria

Address

1 North Waukegan Road, North Chicago, IL, USA, 60064-6400

Website

http://www.abbvieinvestor.com

AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Executives

Nicholas Donoghoe	officer: SVP, Enterprise Innovation	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Susan E Quaggin	director	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Jennifer L. Davis	director	1 PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202
Richard A Gonzalez	officer: Chairman of the Board and CEO	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Elaine K. Sorg	officer: Sr. V.P., U.S. Commercial Ops.	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Perry C Siatis	officer: EVP, GC and Secretary	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Jeffrey Ryan Stewart	officer: SVP, US Commercial Operations	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Kevin K Buckbee	officer: SVP, Controller	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Scott T Reents	officer: SVP, Chief Financial Officer	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Azita Saleki-gerhardt	officer: SVP, Operations	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Carrie C Strom	officer: SVP & Pres Global Allerg Aesth	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Roxanne S Austin	director	200 N SEPULVEDA BLVD, PO BOX 956 MS ES/001/A102, EL SEGUNDO CA 90245
Timothy J. Richmond	officer: EVP, Chief HR Officer	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Michael Severino	officer: EVP, R&D and CSO	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Henry O Gosebruch	officer: Chief Strategy Officer	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092